US Broker Ratings

OrthoPediatrics Corp. (KIDS) Investor Outlook: A 66.54% Potential Upside in Pediatric Orthopedic Innovation

OrthoPediatrics Corp. (NASDAQ: KIDS), a specialized medical device company headquartered in Warsaw, Indiana, is making waves in the healthcare sector, particularly within the niche market of pediatric orthopedics. With a..

Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a 205.95% Upside Potential in Cancer Treatment Innovations

Kura Oncology, Inc. (NASDAQ: KURA) is gaining the attention of investors with its promising pipeline in the biotechnology sector, particularly in the niche of cancer therapeutics. Based in San Diego,..

Xencor, Inc. (XNCR) Investor Outlook: Exploring a Potential 183.53% Upside in Biotech

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company based in Pasadena, California, has recently captured investor attention with a potential upside of 183.53%, according to analyst ratings and targets. Specializing..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Uncovering a 102% Potential Upside for Investors

AbCellera Biologics Inc. (NASDAQ: ABCL), a trailblazing Canadian biotech company, is making significant strides in the healthcare sector with its cutting-edge antibody-based medicines. As the company continues to make advancements..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Biotechnology Innovator with 64% Potential Upside

Cogent Biosciences, Inc. (NASDAQ: COGT), headquartered in Waltham, Massachusetts, is capturing investor attention with its strategic focus on precision therapies for genetically defined diseases. As a key player in the..

Arcus Biosciences, Inc. (RCUS) Investor Outlook: A Biotech with 146.64% Upside Potential

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, is emerging as a compelling opportunity in the biotechnology sector. With an impressive potential upside of 146.64%, as indicated by the..

Replimune Group, Inc. (REPL)

⚠️ No article content returned.

..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Promising Biotech with 60% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology firm based in New York, is making waves in the healthcare sector with its innovative approach to tackling severe autoimmune and inflammatory..

Arbutus Biopharma Corporation (ABUS) Investor Outlook: Exploring a 522% Revenue Growth in the Biotech Arena

Arbutus Biopharma Corporation (NASDAQ: ABUS) has been a focal point in the biotechnology sector, capturing the attention of investors with its remarkable revenue growth and strategic advancements in the field..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: A Biotech Gem with a 47.85% Upside Potential

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a noteworthy player in the healthcare sector, particularly within the biotechnology industry. Headquartered in San Diego, California, the company operates in two main..

Avadel Pharmaceuticals plc (AVDL) Investor Outlook: Exploring a 27% Potential Upside with Strong Buy Ratings

Avadel Pharmaceuticals plc (NASDAQ: AVDL) has been attracting attention in the healthcare sector, particularly within the specialty and generic drug manufacturing industry. Headquartered in Dublin, Ireland, Avadel is making strides..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a Potential 133.99% Upside in the Biotech Sector

Gyre Therapeutics, Inc. (NASDAQ:GYRE), a dynamic player in the biotechnology sector, presents a compelling investment opportunity with a remarkable potential upside of 133.99%, according to analyst ratings. Based in San..

Savara, Inc. (SVRA) Stock Analysis: A 172% Upside Potential in the Biotechnology Sector

For investors with a keen eye on the healthcare sector, specifically in biotechnology, Savara, Inc. (SVRA) presents an intriguing opportunity. With its focus on developing treatments for rare respiratory diseases,..

Immatics N.V. (IMTX) Investor Outlook: A Biotech Gem with 130% Upside Potential

Investors with an eye for biotechnology companies should take notice of Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical firm that has carved out a niche in the burgeoning field of..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Exploring a 162% Potential Upside in the Biotech Sector

Bicara Therapeutics Inc. (NASDAQ: BCAX), a promising player in the biotechnology industry, offers investors a substantial potential upside of 162.34%, according to recent analyst ratings. As a clinical-stage biopharmaceutical company..

Ardelyx, Inc. (ARDX) Investor Outlook: Exploring a 70% Upside Potential in Biotechnology

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology company based in Waltham, Massachusetts, stands poised at the intersection of innovative healthcare solutions and promising market potential. With a market cap of $1.61..

InMode Ltd. (INMD) Stock Analysis: Evaluating Growth Potential in the Aesthetic Medical Device Market

InMode Ltd. (NASDAQ: INMD), an Israeli-based company specializing in minimally invasive aesthetic medical devices, has carved out a significant niche within the healthcare sector. Known for its innovative radio frequency..

Embecta Corp. (EMBC) Stock Analysis: Exploring a Potential 8.86% Upside in the Healthcare Sector

Embecta Corp. (NASDAQ: EMBC), a company with nearly a century of heritage, continues to make its mark in the medical instruments and supplies industry. Specializing in solutions for diabetes management,..

Intellia Therapeutics (NTLA) Stock Analysis: A Deep Look into Its 201.70% Potential Upside

In the dynamic landscape of biotech investments, Intellia Therapeutics, Inc. (NASDAQ: NTLA) emerges as a compelling player with significant growth potential. With its focus on pioneering gene editing treatments, this..

CureVac N.V. (CVAC) Stock Analysis: Navigating the mRNA Frontier with a $1.21 Billion Market Cap

CureVac N.V. (NASDAQ: CVAC), a German biopharmaceutical company, is making headlines in the biotechnology sector with its focus on messenger ribonucleic acid (mRNA) technologies. Despite the volatile nature of biotech..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds